Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial.

ABSTRACT: INTRODUCTION: The PACS01 trial has demonstrated that docetaxel addition to adjuvant anthracycline-based chemotherapy improves disease-free survival (DFS) and overall survival of node-positive early breast cancer (EBC). We searched for prognostic and predictive markers for docetaxel benefit. METHODS: Tumor samples from 1.099 recruited women were analyzed for the expression of 34 selected proteins using immunohistochemistry. The prognostic and predictive values of each marker and four molecular subtypes (luminal A, luminal B, HER2-overexpressing, and triple-negative) were tested. RESULTS: Progesterone receptor-negativity (HR=0.66; 95%CI 0.47-0.92, P=0.013), and Ki67-positivity (HR=1.53; 95%CI 1.12-2.08, P=0.007) were independent adverse prognostic factors. Out of the 34 proteins, only Ki67-positivity was associated with DFS improvement with docetaxel addition (adjusted HR=0.51, 95%CI 0.33-0.79 for Ki67-positive versus HR=1.10, 95%CI 0.75-1.61 for Ki67-negative tumors, P for interaction=0.012). Molecular subtyping predicted the docetaxel benefit, but without providing additional information to Ki67 status. The luminal A subtype did not benefit from docetaxel (HR=1.16, 95%CI 0.73-1.84); the reduction in the relapse risk was 53% (HR=0.47, 95%CI 0.22-1.01), 34% (HR=0.66, 95%CI 0.37-1.19), and 12% (HR=0.88, 95%CI 0.49-1.57) in the luminal B, HER2-overexpressing, and triple-negative subtypes, respectively. CONCLUSIONS: In patients with node-positive EBC receiving adjuvant anthracycline-based chemotherapy, the most powerful predictor of docetaxel benefit is Ki67-positivity.

Mots clés

adjuvant docetaxel breast cancer Ki67 molecular subtypes

Domaines

Cancer

Fichier principal

bcr3051.pdf (334.45 Ko)

BCR3051-S1.DOC (59 Ko)

BCR3051-S10.DOC (342.5 Ko)

BCR3051-S11.DOC (51 Ko)

BCR3051-S12.DOC (89.5 Ko)

BCR3051-S13.DOC (317 Ko)

BCR3051-S14.DOC (481.5 Ko)

BCR3051-S2.DOC (96 Ko)

BCR3051-S3.DOC (44 Ko)

BCR3051-S4.PPT (907.5 Ko)

BCR3051-S5.DOC (288.5 Ko)

BCR3051-S6.DOC (286 Ko)

BCR3051-S7.PPT (72.5 Ko)

BCR3051-S8.DOC (46.5 Ko)

BCR3051-S9.DOC (46.5 Ko)

bcr3051.xml (175.26 Ko)

Origine	Fichiers éditeurs autorisés sur une archive ouverte

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Format	Autre

Ed. BMC : Connectez-vous pour contacter le contributeur

https://inserm.hal.science/inserm-00647247

Soumis le : jeudi 1 décembre 2011-17:07:38

Dernière modification le : mercredi 16 octobre 2024-09:00:03

Archivage à long terme le : vendredi 16 novembre 2012-14:05:17

Dates et versions

inserm-00647247 , version 1 (01-12-2011)

Identifiants

HAL Id : inserm-00647247 , version 1
DOI : 10.1186/bcr3051
PUBMED : 22044691

Citer

Jocelyne Jacquemier, Jean-Marie Boher, Henri Roche, Benjamin Esterni, Daniel Serin, et al.. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial.. Breast Cancer Research, 2011, 13 (6), pp.R109. ⟨10.1186/bcr3051⟩. ⟨inserm-00647247⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

INSERM CNRS ICR FNCLCC IGR PAOLI_CALMETTES MARQUIS ICO GAUDUCHEAU

529 Consultations

314 Téléchargements